Toll-Like Receptor Binding

  • Concept: Small molecule therapies, with a specific focus on TLRs, that can be used synergistically with other cancer therapeutics, including other product candidates in our portfolio.
  • Development Approach: Worldwide rights; wholly owned.
  • Lead Candidate: BNT411, our TLR7 agonist product candidate intended for combination therapies.

More about Toll-Like Receptor Bindings

Product Drugclass
Short Description
Toll-Like Receptor Binding
Product Typology

Wir freuen uns auf Ihre Kontaktaufnahme

Temp JS

p4-css-global

p4-css-templates-a

p4-css-templates-b

Temp JS

p4-css-global

p4-css-templates-a

p4-css-templates-b